Correspondingly, sulfasalazine as an anti-rheumatic agent and etoricoxib as a cyclooxygenase-2 inhibitor have similar profiles of adverse drug reactions, including rashes, serious infections, and hypersensitivity reactions (e.g., Stevens-Johnson syndrome, vasculitis, and parapsoriasis) (8, 9). This evidence concerns the gene PTGS2 and parapsoriasis.